Payment overview · 2025
General Payments
$1,895.87
99 reported records · 22 companies
Healthcare provider profile · identity verified
William P Klein, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEWPORT BEACH, CA · NPI 1205834819
Verified facts
What the public records show
CMS Open Payments records show William P Klein, MD received $1,895.87 in general payments during 2025 across 99 reported records.
GENZYME CORPORATION accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $351.62 | 18.6% | 11 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $249.62 | 13.2% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $239.18 | 12.6% | 13 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $147.48 | 7.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.95 | 7.5% | 10 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $120.95 | 6.4% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.05 | 4.5% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $82.53 | 4.3% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $70.96 | 3.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.74 | 3.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.11 | 2.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.90 | 2.7% | 3 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $46.15 | 2.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.10 | 2.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.81 | 1.5% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $21.93 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.54 | 1.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.74 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.59 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.53 | 0.8% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.43 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.96 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,895.87 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $434.15 | 14 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $249.62 | 22 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $147.48 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $141.47 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $123.62 | 8 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $88.35 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $78.77 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $74.08 | 5 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $72.72 | 8 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $70.96 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.11 | 2 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.22 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $41.83 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $2.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 250 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
250 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 79 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 250 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 50 |
| Azithromycin | Azithromycin | 179 | 104 |
| Montelukast Sodium | Montelukast Sodium | 178 | 52 |
| Lisinopril | Lisinopril | 170 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 37 |
| Prednisone | Prednisone | 135 | 88 |
| Meloxicam | Meloxicam | 128 | 33 |
| Losartan Potassium | Losartan Potassium | 104 | 33 |
| Eliquis | Apixaban | 90 | 26 |
| Metformin Hcl | Metformin Hcl | 87 | 27 |
| Methylprednisolone | Methylprednisolone | 86 | 59 |
| Simvastatin | Simvastatin | 82 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 27 |
| Alprazolam | Alprazolam | 74 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 15 |
| Atenolol | Atenolol | 67 | 19 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Finasteride | Finasteride | 66 | 23 |
| Furosemide | Furosemide | 59 | 19 |
| Gabapentin | Gabapentin | 57 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 14 |
| Famotidine | Famotidine | 46 | 16 |
| Omeprazole | Omeprazole | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 11 |
| Allopurinol | Allopurinol | 43 | 12 |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Januvia | Sitagliptin Phosphate | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | 11 |
| Estradiol | Estradiol | 38 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Levofloxacin | Levofloxacin | 24 | 16 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Ramipril | Ramipril | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 19 | 15 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Rifampin | Rifampin | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,895.87 · 99 records | GENZYME CORPORATION | AVYCAZ, Arikayce, Brinsupri, CAPVAXIVE, CT THROMBECTOMY SYSTEM KIT, CUVITRU, Cologuard Collection Kit, DALVANCE, DUPIXENT, EMBLAVEO, EVENITY, FASENRA, FLOWTRIEVER CATHETER, S, GEMTESA, KISUNLA, LEQVIO, MOUNJARO, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OTEZLA, Ohtuvayre, PANZYGA, PEMGARDA, PROLIA, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REPATHA, SHINGRIX, TEFLARO, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN, ZEPBOUND, Zemaira | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error